Curis’ (CRIS) Buy Rating Reiterated at HC Wainwright

Curis (NASDAQ:CRIS)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $43.00 target price on the biotechnology company’s stock.

Other research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Curis to a “strong sell” rating in a research report on Saturday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a report on Friday, July 17th. Finally, Zacks Research cut Curis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 11th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $43.00.

Curis Price Performance

Shares of NASDAQ:CRIS opened at $1.80 on Monday. The company has a market cap of $3.76 million, a PE ratio of -0.13 and a beta of 3.13. Curis has a 1 year low of $1.54 and a 1 year high of $39.00. The stock’s 50-day moving average is $5.84 and its 200 day moving average is $11.69.

Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($4.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($6.95) by $2.93. Curis had a negative net margin of 80.29% and a negative return on equity of 4,169.81%. Analysts expect that Curis will post -33.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Curis

Several institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC lifted its position in Curis by 71.8% in the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 10,586 shares in the last quarter. Focused Wealth Management Inc bought a new stake in shares of Curis in the 2nd quarter worth $26,000. XTX Topco Ltd purchased a new position in shares of Curis in the fourth quarter worth $26,000. BlackRock Inc. bought a new position in shares of Curis during the second quarter valued at $28,000. Finally, Squarepoint Ops LLC lifted its holdings in shares of Curis by 46.2% during the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 27,343 shares in the last quarter. Institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.